Kashiv BioSciences Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
351
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
2
- Investments
-
1
Kashiv BioSciences General Information
Description
Provider of pharmaceutical research and drug delivery services intended to create improved versions of known medicines with clinical differentiation and compelling value propositions. The company engages in the development of drug delivery platforms, healthcare technologies, improved medicines and life-cycle management products for patients and physicians, helping improve the lives of patients suffering from cancer and meet unmet medical needs.
Contact Information
Website
www.kashivbiosciences.comCorporate Office
- 20 New England Avenue
- Piscataway, NJ 08854
- United States
Corporate Office
- 20 New England Avenue
- Piscataway, NJ 08854
- United States
Kashiv BioSciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kashiv BioSciences Comparisons
Industry
Financing
Details
Kashiv BioSciences Competitors (1)
One of Kashiv BioSciences’s competitors is Nemera, a Private Equity-Backed company based in Lyon, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nemera | Private Equity-Backed | Lyon, France |
Kashiv BioSciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kashiv BioSciences Patents
Kashiv BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023296821-A1 | An improved assay method of antibody | Pending | 29-Jun-2022 | ||
| EP-4419912-A1 | An improved assay method of antibody | Pending | 29-Jun-2022 | ||
| AU-2023250258-A1 | An improved cell culture process for production of protein | Pending | 06-Apr-2022 | ||
| US-20230303621-A1 | Improved process for the separation and analysis of pancreatic enzymes | Pending | 23-Mar-2022 | ||
| AU-2023239069-A1 | An improved process for the separation and analysis of pancreatic enzymes | Pending | 23-Mar-2022 | C07K1/20 |
Kashiv BioSciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kashiv BioSciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kashiv BioSciences Acquisitions (1)
Kashiv BioSciences’s most recent deal was a Merger/Acquisition with Adello Biologics. The deal was made on 03-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Adello Biologics | 03-Jan-2019 | Merger/Acquisition | Biotechnology |
Kashiv BioSciences FAQs
-
When was Kashiv BioSciences founded?
Kashiv BioSciences was founded in 2010.
-
Where is Kashiv BioSciences headquartered?
Kashiv BioSciences is headquartered in Piscataway, NJ.
-
What is the size of Kashiv BioSciences?
Kashiv BioSciences has 351 total employees.
-
What industry is Kashiv BioSciences in?
Kashiv BioSciences’s primary industry is Drug Delivery.
-
Is Kashiv BioSciences a private or public company?
Kashiv BioSciences is a Private company.
-
What is Kashiv BioSciences’s current revenue?
The current revenue for Kashiv BioSciences is .
-
Who are Kashiv BioSciences’s investors?
New Jersey Division of Investment, Avtar Investments, and Tarsadia Investments have invested in Kashiv BioSciences.
-
Who are Kashiv BioSciences’s competitors?
Nemera is a competitor of Kashiv BioSciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
